Cutaneous Pseudolymphoma: A Brief Review and Report of a Case Treatment Using Rituximab
DOI:
https://doi.org/10.21276/apalm.2188Keywords:
cutaneous pseudolymphoma, cutaneous lymphoid hyperplasia, rituximabAbstract
Cutaneous pseudolymphoma (C-PSL) is characterized by heterogenous lymphoproliferative processes contributing to skin lesions which histologically and clinically mimic malignant cutaneous lymphomas. It is of most importance to diagnose such case precisely and discriminate them from malignant lymphomas since treatment protocols are distinctive. Standard medical approaches for C-PSL includes elimination of causative factors, topical, intralesional and systemic steroids, hydroxychloroquine, and photodynamic therapy. Rituximab as an anti CD20 monoclonal antibody was used in this study to treat a patient with 8 years clinical features of pseudolymphoma with no positive response to routine medications. Follow up of almost more than 18 months revealed a successful treatment without noticeable side effects or disease recurrence.
References
1. Sequeira F, Jayaseelan E, Stephen J. (2014 Paraphenylenediamine-induced cutaneous pseudolymphoma. IJD. 2014;59[4]:424.
2. Nnebe NV, Woon C, Haines S, Dayton V, Weigel BJ. Cutaneous pseudolymphoma: an unusual presentation of a scalp mass. Pediatric blood & cancer. 2009;52[2]:283-5.
3. Stoll DM. Treatment of cutaneous pseudolymphoma with hydroxychloroquine. Journal of the American Academy of Dermatology. 1983;8[5]:696-9.
4. Dragonetti E, Cianchini G, Mastrangelo L, Mellone P, Baldi A. Cutaneus pseudolymphoma: a case report. in vivo. 2004;18[5]:549-52.
5. Martin SJ, Duvic M. Treatment of cutaneous lymphoid hyperplasia with the monoclonal anti-CD20 antibody rituximab. Clinical Lymphoma Myeloma and Leukemia. 2011;11[3]:286-8.
6. McLaughlin P, Grillo-López AJ, Link BK, Levy R, Czuczman MS, Williams ME, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. Journal of clinical oncology. 1998;16[8]:2825-33.
7. Weiner GJ, editor. Rituximab: mechanism of action. Seminars in hematology; 2010: Elsevier.
8. Czuczman MS, Olejniczak S, Gowda A, Kotowski A, Binder A, Kaur H, et al. Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels. Clinical Cancer Research. 2008;14[5]:1561-70.
9. Harjunpaa A, Junnikkala S, Meri S. Rituximab [anti-CD20] therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms. Scandinavian journal of immunology. 2000;51[6]:634.
10. Reff ME, Carner K, Chambers K, Chinn P, Leonard J, Raab R, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83[2]:435-45.
11. Van der Kolk L, Grilloâ€López A, Baars J, Hack C, Van Oers M. Complement activation plays a key role in the sideâ€effects of rituximab treatment. British journal of haematology. 2001;115[4]:807-11.
12. Weng W-K, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. Journal of clinical oncology. 2003;21[21]:3940-7.
13. Dalle S, Dupire S, Brunet-Manquat S, Reslan L, Plesa A, Dumontet C. In vivo model of follicular lymphoma resistant to rituximab. Clin. Cancer Res. h. 2009;15[3]:851-7.
14. Robak T. GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies. Curr Opin Investig Drugs. 2009;10[6]:588-96.
15. Klepfish A, Schattner A, Ghoti H, Rachmilewitz EA. Addition of fresh frozen plasma as a source of complement to rituximab in advanced chronic lymphocytic leukaemia. Lancet Oncol. 2007;8[4]:361-2.
2. Nnebe NV, Woon C, Haines S, Dayton V, Weigel BJ. Cutaneous pseudolymphoma: an unusual presentation of a scalp mass. Pediatric blood & cancer. 2009;52[2]:283-5.
3. Stoll DM. Treatment of cutaneous pseudolymphoma with hydroxychloroquine. Journal of the American Academy of Dermatology. 1983;8[5]:696-9.
4. Dragonetti E, Cianchini G, Mastrangelo L, Mellone P, Baldi A. Cutaneus pseudolymphoma: a case report. in vivo. 2004;18[5]:549-52.
5. Martin SJ, Duvic M. Treatment of cutaneous lymphoid hyperplasia with the monoclonal anti-CD20 antibody rituximab. Clinical Lymphoma Myeloma and Leukemia. 2011;11[3]:286-8.
6. McLaughlin P, Grillo-López AJ, Link BK, Levy R, Czuczman MS, Williams ME, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. Journal of clinical oncology. 1998;16[8]:2825-33.
7. Weiner GJ, editor. Rituximab: mechanism of action. Seminars in hematology; 2010: Elsevier.
8. Czuczman MS, Olejniczak S, Gowda A, Kotowski A, Binder A, Kaur H, et al. Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels. Clinical Cancer Research. 2008;14[5]:1561-70.
9. Harjunpaa A, Junnikkala S, Meri S. Rituximab [anti-CD20] therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms. Scandinavian journal of immunology. 2000;51[6]:634.
10. Reff ME, Carner K, Chambers K, Chinn P, Leonard J, Raab R, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83[2]:435-45.
11. Van der Kolk L, Grilloâ€López A, Baars J, Hack C, Van Oers M. Complement activation plays a key role in the sideâ€effects of rituximab treatment. British journal of haematology. 2001;115[4]:807-11.
12. Weng W-K, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. Journal of clinical oncology. 2003;21[21]:3940-7.
13. Dalle S, Dupire S, Brunet-Manquat S, Reslan L, Plesa A, Dumontet C. In vivo model of follicular lymphoma resistant to rituximab. Clin. Cancer Res. h. 2009;15[3]:851-7.
14. Robak T. GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies. Curr Opin Investig Drugs. 2009;10[6]:588-96.
15. Klepfish A, Schattner A, Ghoti H, Rachmilewitz EA. Addition of fresh frozen plasma as a source of complement to rituximab in advanced chronic lymphocytic leukaemia. Lancet Oncol. 2007;8[4]:361-2.
Downloads
Published
17-03-2019
How to Cite
1.
Neilagh AM, Barenji MA, Sharif SB. Cutaneous Pseudolymphoma: A Brief Review and Report of a Case Treatment Using Rituximab. Ann of Pathol and Lab Med [Internet]. 2019 Mar. 17 [cited 2024 Oct. 30];6(3):C22-25. Available from: https://pacificejournals.com/journal/index.php/apalm/article/view/2188
Issue
Section
Case Report
License
Copyright (c) 2019 Akbar Mokhtarpour Neilagh, Mahdi Aghazadeh Barenji, Shahin Behrouz Sharif
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access at http://opcit.eprints.org/oacitation-biblio.html).
